NEW REPORT: Europe In Vitro Diagnostics Market is Projected to Grow at a CAGR of 4.87% as Point-of-Care Testing and Home Diagnostics Go Mainstream

Market Overview

The Europe in vitro diagnostics market size is projected to grow at a CAGR of 4.87% during the forecast period 2025-2033. Factors such as growing incidences of chronic illnesses, increasing geriatric population, investments in healthcare, and adoption of advanced technologies like AI and machine learning in diagnostics are boosting market growth. The shift towards personalized medicine and stringent regulations supporting safety and efficacy also contribute to the expansion.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Europe In Vitro Diagnostics Market Key Takeaways

• CAGR: 4.87% (2025-2033)
• Forecast Period: 2025-2033
• The increasing focus on improving healthcare infrastructure across Europe is propelling market growth.
• Utilization of advanced technologies such as artificial intelligence (AI) and machine learning (ML) in diagnostics is improving precision and efficiency.
• Growing incidences of chronic diseases including diabetes and cardiovascular diseases necessitate early and accurate diagnostics.
• The rising geriatric population demands more extensive and frequent diagnostic testing.
• Shift towards personalized medicine is facilitating demand for advanced in vitro diagnostic tools.
• Introduction of stringent regulations ensures safety, efficacy, and environmental sustainability of IVD products.

Download a sample copy of the report: https://www.imarcgroup.com/Europe-In-Vitro-Diagnostics-Market/requestsample

Market Growth Factors

The growth of the Europe in vitro diagnostics (IVDs) market can be attributed to priorities set by European governments and regulatory bodies to improve the healthcare infrastructure, which in turn accelerates the adoption of advanced diagnostic devices, thereby creating a wider market opportunity. Dramatic investments from public and private healthcare providers in diagnostic capabilities drive market growth.

Market growth is driven by the adoption of machine learning (ML) and artificial intelligence (AI) technologies as a major factor. AI and ML technologies allow for diagnosis of more precision with fewer errors and faster results which is critical in the identification and treatment of diseases in healthcare applications.

The rise in prevalence of chronic diseases, such as diabetes and cardiovascular diseases, which require an early diagnosis and constant monitoring, is expected to be another major growth driver of the European IVD market. The increase in the geriatric population in Europe is projected to increase the demand for constant health assessment and monitoring. The move toward personalized, or precision medicine is also anticipated to help drive the market by allowing tests to be tailored to each individual patient.

Market Segmentation

Test Type:

The market is segmented into Clinical Chemistry, Molecular Diagnostics, Immunodiagnostics, Hematology, and Others. These test types cover a comprehensive range of diagnostic categories essential for disease detection and therapeutic monitoring.

Product: 

Segmentation includes Reagent and Kits, and Instruments. These components are critical for executing diagnostic procedures with accuracy and efficiency.

Usability: 

Includes Disposable IVD Devices and Reusable IVD Devices, catering to different healthcare settings and operational preferences.

Application: 

Includes Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, and Others. These applications highlight the diverse clinical areas where in vitro diagnostics play a crucial role.

End User: 

The market serves Hospitals Laboratories, Clinical Laboratories, Point-of-care Testing Centers, Academic Institutes, Patients, and Others, demonstrating the wide range of healthcare providers and recipients.

Regional Insights

The report identifies Germany, France, United Kingdom, Italy, Spain, and other countries as the major regional markets within Europe. This broad geographic coverage supports diverse healthcare infrastructures and demand dynamics. The market growth in these regions is driven by increased healthcare investments, rising disease prevalence, and government initiatives enhancing diagnostic capabilities.

Key Players

• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Abbott Laboratories
• Danaher Corporation
• BioM 9rieux SA
• QIAGEN N.V.
• SYNLAB Group
• DiaSorin S.p.A.
• Tecan Group Ltd.
• Leica Biosystems

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302